

# Invitation to subscribe for units

Clinical Laserthermia Systems AB | 556705-8903

**Subscription period: 19 June – 3 July 2023**

## IMPORTANT INFORMATION TO THE READER

This information brochure constitutes marketing and is not a prospectus within the meaning of Regulation (EU) 2017/1129 of the European Parliament and of the Council. The invitation to subscribe for securities in Clinical Laserthermia Systems AB ("CLS" or the "Company") is made only by means of the prospectus published on the 12 June 2023 (the "Prospectus"), which is available, inter alia, on CLS website ([www.clinicallaser.se](http://www.clinicallaser.se)).

A prospectus has been drafted in connection with the rights issue. The prospectus has been reviewed and approved by the Swedish Financial Supervisory Authority ("Finansinspektionen"). Finansinspektionen's approval should not be regarded as any kind of support for CLS or support for the quality of the securities offered and does not mean that Finansinspektionen guarantees that the factual information in the prospectus (or information brochure) is correct or complete. The Prospectus contains a description of the risks and potential benefits associated with an investment in the Company and potential investors are recommended to read the Prospectus in its entirety before making an investment decision.

This information brochure may not be distributed, published or released in or into the United States, Australia, Japan, Canada, New Zealand, South Africa, Hong Kong, Switzerland, Singapore, South Korea, Russia or Belarus. The information brochure may not be sent to persons in these countries or any other jurisdiction to which it is unlawful to deliver unit rights, BTUs or new shares and/or warrants, except in accordance with applicable law and provided that no further prospectus, registration or other action is required in addition to what is required by Swedish law. Unless expressly stated otherwise in the Prospectus, unit rights, BTUs or new shares and/or warrants may not be offered, sold, transferred or delivered, directly or indirectly, in or into any of these countries.

Please note that this document has been translated from Swedish. The Swedish version shall govern for all purposes and prevail in case of any discrepancy with this English version.

[www.clinicallaser.se](http://www.clinicallaser.se)

# CEO comments

**Over the last year, we at CLS have achieved several important milestones. We have executed on our strategic plan in the journey towards our vision to establish minimally invasive laser ablation performed with CLS products as an effective standard treatment in the urology and neurosurgery segment. The markets are driven by a strong demand for an alternative treatment avoiding the use of traditional open surgery, which carries significantly higher risks for patients.**

**In collaboration with ClearPoint Neuro**, we have completed a clinical study on an MRI image-guided laser ablation treatment of glioblastoma at Skåne University Hospital in Lund. Glioblastoma is the most common and most aggressive form of brain tumor, for which 300–400 patients per annum are currently operated on in Sweden, using open surgery. Combined with ClearPoint Neuro's stereotaxy solution, we have a competitive product offering. As the only one-stop-shop solution on the market, we offer more efficient use of time and resources in clinics, whilst paving the way for treatment of patients with hard-to-reach brain tumors. These patients have previously been left untreated due to the excessive risks associated with traditional open surgery. We are pleased to announce that the last patient in the initial study was treated in the second quarter of 2023 and that the study is now being extended with an additional 10 patients following the approval by the Swedish Medical Products Agency. Meanwhile, a limited market launch of our 510(k)-cleared product for the treatment of brain tumors and drug-resistant epilepsy is currently underway in the US.

**With our TRANBERG products**, we also offer an early treatment alternative to the approximately 1.5 million patients that are diagnosed with localized prostate cancer, in the world, each year. In the first half of 2023, we signed a strategic agreement with Soteria Medical, which has a navigation system for MRI-guided prostate procedures, where we will jointly market and sell the companies' combined products in our markets outside the US. We have also signed a Mobile Service Provider agreement with AVANT Concierge Urology whereby CLS provides the TRANBERG Thermal Therapy System, with consumables, training and on-site clinical and technical support to AVANT clinicians and personnel, against a fee per treatment. The first three patients were treated already in May this year. Our clinical program is ongoing and growing, to effectively support the launch and commercialization of these product offerings.

**I am very pleased** with the great position CLS has established for continued market penetration and commercialization where we aim to reach a positive cash flow measured as EBITDA in 2025 with sales revenues corresponding to SEK 100 million. We predict that the urology segment in the US will be the main contributor to sales. I would now like to invite you to join us on our continued journey at CLS. We look forward to sharing important advancements with the market as we pass clinical, regulatory, and commercial milestones.

**The rights issue gives us** an improved capital structure from which to work as well as enabling implementation of our strategic plan against set targets for growth and profitability.

**Welcome to invest in CLS!**

**Dan J. Mogren**

CEO Clinical Laserthermia Systems AB

# About CLS

Clinical Laserthermia Systems is a medtech company that develops and sells products for minimally invasive image-guided laser treatment of prostate cancer, brain tumors, drug-resistant epilepsy and metastatic (spread) cancer. The product portfolio is marketed by CLS under the trademark TRANBERG® and by the Company's partner and global distributor, Clearpoint Neuro Inc. under the trademark Clearpoint Prism™. In combination with various imaging systems, such as ultrasound (UL) and magnetic resonance imaging (MRI), the market is offered integrated systems image-guided laser ablation with high-precision.

The Board of Directors deems that there is a significant global need for this type of treatment and the Company has since 2018 worked to develop a second generation of its technology platform, which was launched in 2022. The new generation can be integrated with existing imaging systems, mainly UL and MRI, as well as image-guided instrument navigation and positioning systems for use in the urology and neurosurgery market segments. In addition to urology and neurosurgery, CLS' new generation of TRANBERG® products is also adapted for another segment, namely oncology.



**"I am very pleased with the great position CLS has established for continued market penetration and commercialization where we aim to reach a positive cash flow measured as EBITDA in 2025 with sales revenues corresponding to SEK 100 million."**

# The offer in brief

<b>Subscription period:</b>	19 June – 3 July 2023.
<b>Subscription price:</b>	SEK 2.50 per unit, corresponding to SEK 0.10 per new B-share. The warrants of series TO 6 B are issued free-of-charge.
<b>Issue volume:</b>	The offer comprises a maximum of 54,281,479 units, consisting of 1,357,036,975 new B-shares and 271,407,395 new warrants of series TO 6 B. The Company can initially be provided proceeds of a maximum amount of approximately SEK 135.7 million before deduction of transaction related costs. Through the exercise of warrants of series TO 6 B, the Company may in February 2024 be provided with an additional maximum amount of approximately SEK 54.3 million before deduction of transaction related costs.
<b>Preferential right to subscription:</b>	Those who on the record date 15 June 2023, were registered as shareholders in the Company have preferential right to subscribe for units in the rights issue in relation to previous holdings, whereby one (1) existing share, regardless the share class, gives one (1) unit right. Three (3) unit rights entitle to subscribe for one (1) unit. Each unit consists of twenty-five (25) new B-shares and five (5) warrants of series TO 6 B.
<b>Trading in unit rights:</b>	Trading in unit rights will take place on Nasdaq First North Growth Market during the period 19 June 2023 to and including 28 June 2023.
<b>Trading in BTU:</b>	Trading in paid subscribed units (BTU) will take place on Nasdaq First North Growth Market during the period from 19 June 2023 until the Swedish Companies Registration Office has registered the rights issue. The last day for trading in BTUs will be announced via a separate press release after the completion of the rights issue.
<b>Pre-subscription and underwriting commitments:</b>	Up to approximately 84 percent (corresponding to approximately SEK 114 million) of the initial part of the rights issue is covered by pre-subscription and underwriting commitments from Board of Directors, management, existing owners, the Company's current lenders Buntel AB, Lubrica Equity AB and Formue Nord Fokus A/S as well as external qualified investors.
<b>Warrant of series TO 6 B:</b>	Holders of warrants of series TO 6 B have, during the exercise period from 23 January 2024 to and including 6 February 2024, the right to subscribe for a new B-share in the Company for each warrant. The subscription price in the following warrant exercise amounts to seventy (70) percent of the average volume-weighted price for the B-share according to Nasdaq First North Growth Market's official price statistics during a period of 10 trading days ending two (2) banking days before the exercise period begins. The Company will publish the subscription price the day before the first day of the exercise period. The subscription price shall be rounded to the nearest whole Swedish öre. The subscription price shall not exceed SEK 0.20 per new B-share and not be less than the share's quota value.

## Investment highlights



Meets a broad clinical need



Recurring revenue model



Great market potential in the US



CLS has established market firms



Several market approvals in place



A favorable gross margin



Facing acceleration



Partnership with leading companies



CLS aims to achieve a positive operating profit (EBITDA) in the financial year 2025. To accomplish this, the Company estimates that sales of around SEK 100 million are required for the same year, with a focus on the US market, representing around 70 percent of the total sales, as well as increased sales in the EU by the end of 2024. Over 65 percent of the sales are expected to originate from the urology segment. The table below presents key objectives achieved as well as the Company's objectives and ambitions for the period, which are linked to the activities that the rights issue, as well as the exercise of warrants of series TO 6 B, intends to finance.

### Within the urology market segment

#### US

Launch CLS UL-based treatment systems for focal FLA treatment of localized prostate cancer in urology clinics and radiology departments. - **Achieved**

Continue to develop clinical evidence for CLS UL-based treatment systems for focal FLA treatment of localized prostate cancer. - **2023-24**

Obtain US-FDA market approval (510(k) clearance) for the CLS MRI-based treatment system for focal FLA treatment of localized prostate cancer in radiology departments. - **2023**

Launch the CLS MRI-based treatment system for focal FLA treatment of localized prostate cancer in radiology departments. - **2024**

Enter into two to three new agreements with commercial partners for further expansion of sales and distribution in the US. - **2023-24**

Conduct eight new commercial customer installations of treatment systems in the US. - **2023**

#### EUROPE

Product launch of CLS UL-based and MRI-based treatment systems for focal FLA treatment of localized prostate cancer in urology clinics and radiology departments. - **Achieved**

Continue to develop supporting clinical evidence in Europe for CLS UL and MRI-based treatment systems for focal FLA treatment of localized prostate cancer. - **2023-24**

Enter into one to two new agreements with commercial partners for further expansion of sales and distribution in Europe. - **2023**

Conduct four new commercial customer installations of treatment systems in Europe. - **2023**

#### ASIA-PACIFIC REGION

Obtain market approval in Singapore for MRI and UL-based treatment systems for focal FLA treatment of localized prostate cancer in radiology departments and urology clinics. - **2023**

Enter into two to three new agreements with commercial partners for further expansion of sales and distribution in the Asia-Pacific region. - **2023-24**

Conduct four new commercial customer installations in the Asia-Pacific region. - **2023**

### Within the neurosurgery market segment

#### US

Obtain US-FDA market approval (US-FDA 510(k) clearance) for the CLS MRI-based treatment system for focal LITT treatment of brain lesions in radiology or neurosurgery departments. - **Achieved**

Market launch via Clearpoint Neuro of CLS MRI-based integrated treatment systems for focal LITT treatment of brain lesions in radiology or neurosurgery departments in four to six hospitals. - **Achieved**

#### EUROPE

Generation of initial clinical evidence in Europe for future CE marking of CLS MRI-based treatment systems for focal LITT treatment of brain lesions.

*Ongoing clinical study, Skåne University Hospital, Lund.* - **Achieved**

Initiate expansion of clinical evidence generation in Europe for CE marking of the CLS MRI-based treatment system for focal LITT treatment of brain lesions.

*Approximately 20-30 patients in neurosurgery clinics in Europe.* - **2023**

### Other operational objectives

Ensure certification and CE marking of the product in Europe according to MDD/MDR. - **2023-24**

Undertake recruitments as well as enter into partnerships to secure the expertise and resources necessary within clinical support for CLS' commercial objectives in the urology segment in Europe, the US and Asia-Pacific. - **2023-24**

Enter into agreements with "second source" suppliers for critical components and materials to ensure the necessary capacity and security in the supply chain. - **2023-24**

# Terms and conditions for the offer

## Preferential right to subscription

Parties who on the record date 15 June 2023 are registered as shareholders in the share register held by Euroclear on behalf of the Company have preferential right to subscribe for new units in relation to the number of shares held on the record date.

For each A- or B-share held on the record date, one (1) unit right is received. The unit rights entitle the holder to subscribe for new units with preferential rights, whereby three (3) unit rights entitle the holder to subscribe for one (1) new unit. One (1) unit consists of twenty-five (25) B-shares and five (5) warrants of series TO 6 B.

## Issue volume

The offer comprises a maximum of 54,281,479 units (newly issued B-shares and attached warrants of series TO 6 B free of charge). The initial issue amount amounts to a maximum of approximately SEK 135.7 million before issue costs.

## Warrant of series TO 6 B

One (1) warrant of series TO 6 B entitles the holder to subscribe for one (1) newly issued B-share in the Company and can be exercised during the period from and including 23 January 2024 to and including 6 February 2024. Provided that the initial issue is fully subscribed and that the attached free of charge warrants of series TO 6 B are fully exercised, the share capital will increase by an additional approximately SEK 25,105,184.175715 (calculated before the reduction of the share capital via the initial part of the rights issue). The subscription price shall not exceed SEK 0.20 per new B-share and not be lower than the share's quota value of approximately SEK 0.09 per share (calculated before the reduction of the share capital via the initial part of the rights issue).

The warrant will be subject to trading on First North from the time the conversion of BTUs has taken place in Euroclear Sweden's system to and including 2 February 2024 and will be traded in Swedish kronor. The warrants of series TO 6 B have ISIN code SE0020388650.

## Subscription price

The subscription price is SEK 2.50 per unit, which means that the price per B-share is SEK 0.10. No brokerage fee will be charged.

## Record date

The record date in Euroclear Sweden for the right to participate in the rights issue is 15 June 2023. The last day of trading in the Company's share with the right to participate in the rights issue is 13 June 2023. The first day of trading in the Company's share without the right to participate in the rights issue is 14 June 2023.

## Subscription period

Subscription of new units with the support of unit rights shall take place during the period from and including 19 June 2023 to and including the 3 July 2023. The Board of Directors of the Company reserves the right to extend the subscription period. Any extension will be announced by the Company through a press release no later than 3 July 2023.

## Unit rights

For each existing A- or B-share held on the record date, one (1) unit right is received. The unit rights entitle the holder to subscribe for new units with preferential rights, whereby three (3) unit rights entitle the holder to subscribe for one (1) new unit.

## Trading with unit rights

Trading in unit rights will take place on First North during the period 19 June 2023 to and including 28 June 2023. Shareholders shall contact their bank or other trustee with the necessary authorization to conduct purchases and sales of unit rights. Unit rights acquired during the forementioned trading period give, during the subscription period, the same right to subscribe for units as the unit rights shareholders receive based on their holdings in the Company on the record date.

## Unexercised unit rights

Unit rights which have not been sold no later than 28 June 2023 or exercised for subscription of units no later than 3 July 2023 will be cancelled from all VP accounts without compensation. No notice will be given in connection with the cancellation of unit rights.

## Issue statement and subscription

### Directly registered shareholders

The shareholders or representatives of shareholders who, on the record date of 15 June 2023, were registered with Euroclear Sweden, will receive a pre-printed issue statement with attached payment receipt, as well as a folder containing a summary of the terms of the rights issue with reference to the full prospectus. Information will be available for download on Nordic Issuing AB's website ([www.nordic-issuing.se](http://www.nordic-issuing.se)), on Sedermera's website ([www.sedermera.se](http://www.sedermera.se)), on Redeye's website ([www.redeye.se](http://www.redeye.se)) as well as on the Company's website ([www.clinicallaser.se](http://www.clinicallaser.se)). Those included in the separate

list of pledge holders etc. maintained in connection with the share register will not receive any information but will be notified separately. A VP notice reporting the registration of unit rights on the shareholder's VP account will not be distributed.

## Subscription with preferential right

Subscription with the support of preferential rights shall take place via simultaneous cash payment no later than 3 July 2023. Subscription via payment shall be made either with the pre-printed payment receipt that is attached to the issue statement, or via payment instructions on the application form for subscription with the support of unit rights according to the following two alternatives:

### Issue statement (pre-printed payment receipt from Euroclear)

If all unit rights received on the record date are exercised for subscription, only the pre-printed payment receipt shall be used as a basis for subscription via cash payment. The subscription is binding.

### Subscription via Nordic Issuing with the support of unit rights

In the event that a different number of unit rights than stated in the pre-printed issue statement is exercised for subscription, e.g. by acquiring or selling unit rights, subscription with the support of unit rights shall be made on Nordic Issuing's platform <https://minasidor.nordic-issuing.se/> and be used as a basis for subscription via cash payment. The shareholder shall log in to the platform and state the number of unit rights to be exercised, the number of units they are subscribing for and the amount to be paid. The subscription is binding.

## Information to banks/trustees regarding subscription

On the first day of the subscription period, Nordic Issuing sends out an email containing the Prospectus, a brief summary of the offer and application forms that all banks/trustees can use for subscription with the support of unit rights for their underlying customers.

Nordic Issuing reserves the right to disregard application forms received by post, as it cannot be guaranteed that they will be received before the last day of the subscription period if they are mailed.

## Nominee-registered shareholders

Shareholders whose holdings of shares in the Company are nominee-registered with a bank or other trustee will not receive an issue statement, however, a folder containing a summary of the terms of the rights issue with reference to the full prospectus will be sent out. Subscription and payment shall instead be made in accordance with instructions from the respective bank or trustee. Please note that when unit rights are exercised via a bank or trustee, this should be done early in the subscription period, as the respective bank/trustee may set different time limits for the last subscription date.

## Subscription without preferential right

Subscription of units without preferential rights shall take place throughout the same period as subscription of units with preferential rights, i.e. from and including 19 June 2023 to and including 3 July 2023. The Board of Directors of the Company reserves the right in all circumstances to extend the subscription period and the time for payment. Any such extension shall be announced no later than the last day of the subscription period and published by the Company.

Application to subscribe for units without preferential rights shall be made on Nordic Issuing's platform <https://minasidor.nordic-issuing.se/>.

For nominee-registered shareholders, application for subscription of units without preferential rights shall be made to the respective trustee and in accordance with instructions from that trustee, or if the holding is registered with several trustees, from each of them. In order to be able to invoke subsidiary preferential rights, it is required that the subscription is carried out through the trustee as there is otherwise no possibility to identify a particular subscriber who has subscribed for units both with and without the support of unit rights.

Incomplete or incorrectly filled-in subscriptions may be disregarded. It is only permitted to apply for one "Subscription without unit rights". The subscription shall be made no later than 3 July 2023. The application is binding.

## Subscription from accounts subject to specific rules

Please note that anyone who has a custody account with specific rules for securities transactions, such as an investment savings account (ISK) or endowment insurance account (KF), must check with the bank or trustee that manages the account whether the acquisition of securities within the framework of the offer is possible. In this case, the application must be made in agreement with the bank/trustee managing the account.

## Subscription over EUR 15,000

If the subscription amounts to or exceeds EUR 15,000, a money laundering form shall be completed and sent to Nordic Issuing in accordance with the Act (2017:630) on measures against money laundering and terrorist financing.

Please note that Nordic Issuing cannot distribute any securities, even though payment have been received, until the money laundering control is received by Nordic Issuing.

#### Shareholders residing abroad

Shareholders residing outside Sweden (however, this does not refer to shareholders residing in the United States, Australia, Japan, Canada, New Zealand, South Africa, Hong Kong, Switzerland, Singapore, South Korea, Russia, Belarus or other countries where participation requires additional prospectus, registration or other measures than those required by Swedish law) and who are entitled to subscribed for units in the rights issue, can contact Nordic Issuing for information about subscription and payment.

Due to the restrictions in the securities legislation in the United States, Australia, Japan, Canada, New Zealand, South Africa, Hong Kong, Switzerland, Singapore, South Korea, Russia, Belarus, or other countries where participation requires additional prospectuses, registration, or other measures than those required by Swedish law, no unit rights will be offered to holders with registered addresses in any of these countries. Accordingly, no offer to subscribe for units in the Company is directed to shareholders in these countries.

Notwithstanding any other provision in this document, the pre-printed issue statement, or the application forms, the Company reserves the right to permit any person to apply for new securities in the rights issue if the Company is convinced that the transaction in question is exempt from or not subject to the laws or regulations giving rise to the restrictions in question.

#### Allocation upon subscription without preferential rights

If not all units are subscribed for with preferential rights in accordance with the above, the Board of Directors shall, within the framework of the maximum amount in the rights issue, decide on the allocation of units to others who have subscribed for units without preferential rights as well as decide how the allocation between subscribers shall be made.

In the first instance, allotment of units subscribed for without unit rights shall be made to such subscribers who have also subscribed for units with unit rights, regardless of whether the subscriber was a shareholder on the record date or not, and in the event that allotment to such subscribers cannot be made in full, allotment shall be made pro rata in relation to the number of unit rights exercised for subscription of units and, to the extent that this cannot be done, by drawing lots.

Secondly, allotment of units subscribed for without unit rights shall be made to others who have subscribed without unit rights, and in the event that allotment to these cannot be made in full, allotment shall be made pro rata in relation to the number of units subscribed for by each person and, to the extent this cannot be done, by drawing lots.

Thirdly, allotment of units subscribed for without unit rights shall be made to the underwriters in proportion to the size of the underwriting commitments, and to the extent this cannot be done, by drawing lots.

#### Notice of allotment of units subscribed for without preferential rights

Notice of any allocation of units, subscribed for without preferential rights, is given by sending an allocation notice in the form of a settlement note via e-mail. Settlement notes are expected to be sent out as soon as possible after the end of the subscription period and payment shall, according to instructions on the settlement note, be made no later than four (4) banking days thereafter. Note that there is no possibility of withdrawing the amount from the specified deposit. If payment is not made in time, units may be allotted to another party. Should the sales price at such allotment be lower than the price according to the offer, the person who originally received the allocation of these units may have to pay all or part of the difference. No notice will be given to those who have not received allocation.

#### Publication of the outcome of the rights issue

The announcement of the outcome of the rights issue is planned to take place around 4-6 July 2023, or as soon as possible after the subscription period has ended. The Company will publish the outcome of the rights issue via a press release.

#### Paid subscribed unit (BTU)

Subscription via payment is registered with Euroclear Sweden as soon as possible, which normally means a few banking days after payment. Thereafter, the directly registered subscriber will receive a VP notice confirming that the paid subscribed units (BTU) have been booked on the subscriber's VP account. Subscribed units are booked as BTU on the VP account until the rights issue has been registered with the Swedish Companies Registration Office.

Shareholders who have their holdings on deposit with a bank or trustee will receive information from the respective bank/trustee.

#### Trading in BTU

Trading in BTU takes place on First North from 19 June 2023 until the rights issue is registered with the Swedish Companies Registration Office. Subscribed units are booked as BTU in the subscriber's VP account or depository until the rights issue has been registered with the Swedish Companies Registration Office, which is expected to take place around 24 July 2023.

#### Delivery of shares and warrants

As soon as the rights issue has been registered with the Swedish Companies Registration Office, which is expected to take place around 24 July 2023, BTU will be converted into B-shares and warrants of series TO 6 B without any notification from Euroclear. Please note that the issue may be partially registered at the Swedish Companies Registration Office.

#### Trading in the share

The B-shares in the Company are listed on First North. The B-shares are traded under the ticker "CLS B" and have ISIN code SE0002756130.

#### Right to dividends

The new shares carry the right to dividends for the first time on the first record date for dividends that occurs after the new shares have been registered with the Swedish Company Registration Office. The new shares give the same right to dividends as the existing shares.

#### Dilution

Through the Rights Issue, CLS's share capital may increase by a maximum of approximately SEK 125,525,920.878575 through a new issue of a maximum of 1,357,036,975 B-shares, corresponding to a maximum dilution of approximately 89.0 percent of the votes and 89.3 percent of the capital in the Company.

In the event that the underwriters choose compensation in the form of units, the subsequent directed set-off issue may lead to an additional dilution of a maximum of approximately 9.7 percent of the votes and 9.7 percent of the capital in the Company, assuming a fully subscribed Rights Issue.

Upon full exercise of the attached warrants of series TO 6 B, the share capital in the Company will increase by an additional maximum of approximately SEK 25,105,184.175715 and the number of B-shares will increase by an additional maximum of 271,407,395 B-shares (calculated before the reduction of the share capital through the initial part of the rights issue), corresponding to an additional dilution of approximately 15.1 percent of the votes and 15.2 percent of the capital in the Company.

Possible recalculation of the subscription price and subscription entitlement The subscription price and the number of shares in the Company that the warrants of series TO 6 B entitle to subscription for may be recalculated in the event of, for example, a bonus issue or new issue. In the event that recalculation becomes relevant, the Company will publish more information about this on its website ([www.clinicallaser.se](http://www.clinicallaser.se)) via a press release.

#### Information about LEI and NCI numbers

According to Directive 2011/61/EU of the European Parliament and of the Council (MiFID II), all investors must have a global identification code from 3 January 2018 in order to carry out transactions in securities. These requirements entail that legal entities must apply for registration of a so-called Legal Entity Identifier (LEI) and physical individuals must find out their National Client Identifier (NCI) in order to subscribe for units in the rights issue. Please note that it is the subscriber's legal status that determines whether an LEI code or NCI number is needed, and that Nordic Issuing may be prevented from executing the transaction for the person in question if the LEI code or NCI number (as applicable) is not provided. Legal entities that need to obtain an LEI code can turn to one of the providers available on the market. Instructions for the global LEI system can be found at [gleif.org](http://gleif.org). For physical individuals who have only a Swedish nationality, the NCI number consists of the designation "SE" followed by the person's social security number. If the person in question has multiple nationalities or something other than a Swedish nationality, the NCI number may be some other type of number. Those who intend to subscribe for units in the rights issue are encouraged to apply for registration of an LEI code (legal entities) or find out their NCI number (physical individuals) in a timely manner in order to be entitled to participate in the rights issue and/or to be allocated new units subscribed for without unit rights.

#### Other

The Board of Directors of the Company is not entitled to suspend, withdraw or temporarily cancel the offer to subscribe for new units in the Company in accordance with the terms of the prospectus.

In the event that an excessive amount has been paid by a subscriber for subscribed units, Nordic Issuing will arrange for the excess amount to be repaid. In such case, Nordic Issuing will contact the subscriber for information about a bank account to which Nordic Issuing can repay the amount. No interest will be paid on excess amounts. Subscription for new units is irrevocable, and the subscriber cannot cancel or modify a subscription for new units. An incomplete or incorrectly completed application form/subscription may be disregarded. If payment for subscribed units is paid too late, is insufficient or is paid incorrectly, the application for subscription may be disregarded or subscription may be carried out for a lower amount. Paid proceeds that has not been utilized will be refunded. If several applications/subscriptions of the same category are submitted, only the application/subscription that was last received by Nordic Issuing will be considered. Late payment of amounts less than SEK 100 will only be refunded upon request.